Decreased Expression of is Associated with Poor Prognosis and Immune Infiltration in Kidney Renal Clear Cell Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Jan 30

PMID 38288038

Authors

Wanlu Liu

Zhen Xiao

Mingyou Dong

Xiaolei Li

Zhongshi Huang

Affiliations

Soon will be listed here.

Abstract

The most prevalent and insidious type of kidney cancer is kidney clear cell carcinoma (KIRC). Thioredoxin-interacting protein () encodes a thioredoxin-binding protein involved in cellular energy metabolism, redox homeostasis, apoptosis induction and inflammatory responses. However, the relationship between , immune infiltration and its prognostic value in KIRC remains unclear. Thus, the present study evaluated the potential for TXNIP as a prognostic marker in patients with KIRC. Data from The Cancer Genome Atlas were used to assess relative mRNA expression levels of in different types of cancer. The protein expression levels of TXNIP were evaluated using the Human Protein Atlas. Enrichment analysis of genes co-expressed with was performed to assess relevant biological processes that may be involved in. CIBERSORT was used to predict the infiltration of 21 tumor-infiltrating immune cells (TIICs). Univariate and multivariate Cox regression analyses were used to assess the relationship between expression and prognosis. Single-cell RNA-sequencing datasets were used to evaluate the mRNA expression levels of in certain immune cells in KIRC. The CellMiner database was used to analyze the relationship between mRNA expression and drug sensitivity in KIRC. The results from the present study demonstrated that expression was significantly decreased in KIRC tissue compared with that in normal tissue, as confirmed by western blotting and reverse transcription-quantitative PCR. In addition, downregulated expression was significantly associated with poor prognosis, a high histological grade and an advanced stage. The Cell Counting Kit-8 assay demonstrated that overexpression significantly suppressed tumor cell proliferation. Univariate and multivariate Cox regression analyses indicated that served as a separate prognostic factor in KIRC. Moreover, expression was significantly correlated with the accumulation of several TIICs and its overexpression significantly downregulated the mRNA expression levels of CD25 and cytotoxic T-lymphocyte-associated protein 4, immune cell surface markers in CD4 T lymphocytes. In conclusion, may be used as a possible biomarker to assess unfavorable prognostic outcomes and identify immunotherapy targets in KIRC.

References

Ao H, Li H, Zhao X, Liu B, Lu L . TXNIP positively regulates the autophagy and apoptosis in the rat müller cell of diabetic retinopathy. Life Sci. 2021; 267:118988. DOI: 10.1016/j.lfs.2020.118988. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

James R, Davidson K, Bosch K, Biechele T, Robin N, Taylor R . WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling. PLoS One. 2012; 7(12):e50457. PMC: 3515623. DOI: 10.1371/journal.pone.0050457. View

Wang S, Liu W, Ly D, Xu H, Qu L, Zhang L . Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2018; 16(1):6-18. PMC: 6318290. DOI: 10.1038/s41423-018-0027-x. View

Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J . Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2009; 11(2):136-40. DOI: 10.1038/ni.1831. View

Hong S, Yu F, Luo Y, Hagen T . Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein. Cell Signal. 2016; 28(5):377-383. DOI: 10.1016/j.cellsig.2016.01.011. View

Shuch B, Amin A, Armstrong A, Eble J, Ficarra V, Lopez-Beltran A . Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2014; 67(1):85-97. DOI: 10.1016/j.eururo.2014.04.029. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Ding Q, Lu P, Xia Y, Ding S, Fan Y, Li X . CXCL9: evidence and contradictions for its role in tumor progression. Cancer Med. 2016; 5(11):3246-3259. PMC: 5119981. DOI: 10.1002/cam4.934. View

10.

Kokubo K, Hirahara K, Kiuchi M, Tsuji K, Shimada Y, Sonobe Y . Thioredoxin-interacting protein is essential for memory T cell formation via the regulation of the redox metabolism. Proc Natl Acad Sci U S A. 2023; 120(2):e2218345120. PMC: 9926250. DOI: 10.1073/pnas.2218345120. View

11.

Haddadi M, Negahdari B . Clinical and diagnostic potential of regulatory T cell markers: From bench to bedside. Transpl Immunol. 2021; 70:101518. DOI: 10.1016/j.trim.2021.101518. View

12.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

13.

Lipson E, Sharfman W, Drake C, Wollner I, Taube J, Anders R . Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2012; 19(2):462-8. PMC: 3548952. DOI: 10.1158/1078-0432.CCR-12-2625. View

14.

Carlo M, Voss M, Motzer R . Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol. 2016; 13(7):420-31. PMC: 5532875. DOI: 10.1038/nrurol.2016.103. View

15.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

16.

Woolston C, Madhusudan S, Soomro I, Lobo D, Reece-Smith A, Parsons S . Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma. Redox Biol. 2013; 1:285-91. PMC: 3757700. DOI: 10.1016/j.redox.2013.04.006. View

17.

Bella L, Zona S, Nestal de Moraes G, Lam E . FOXM1: A key oncofoetal transcription factor in health and disease. Semin Cancer Biol. 2014; 29:32-9. DOI: 10.1016/j.semcancer.2014.07.008. View

18.

Picard E, Verschoor C, Ma G, Pawelec G . Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. Front Immunol. 2020; 11:369. PMC: 7068608. DOI: 10.3389/fimmu.2020.00369. View

19.

Chen D, Dang B, Huang J, Chen M, Wu D, Xu M . MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer. Oncotarget. 2015; 6(32):32701-12. PMC: 4741723. DOI: 10.18632/oncotarget.4702. View

20.

Chatterjee N, Bivona T . Polytherapy and Targeted Cancer Drug Resistance. Trends Cancer. 2019; 5(3):170-182. PMC: 6446041. DOI: 10.1016/j.trecan.2019.02.003. View